Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMGV Regimen for Recurrent Adult AML and MDS-EB-2/Elderly AML
NCT06329999Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Feb 2024
- Primary completion
- Dec 2025
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitoxantrone-liposome in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Ruijin Hospital. Primary endpoint: Composite Complete Remission at 1 year. Started Feb 2024; status: recruiting.
02
Drugs
mitoxantrone-liposome
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06329999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06329999.